Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer

Anaplastic lymphoma kinase fusion gene-positive (ALK+) disease occurs in around 5% of patients with advanced non-small-cell lung cancer (NSCLC) [1]. Alectinib, a potent ALK inhibitor, received full approval from the US Food and Drug Administration on November 6, 2017 for the treatment of patients with advanced ALK+ NSCLC [2].

Source: Lung Cancer - October 13, 2019 Category: Cancer & Oncology Authors: Sai-Hong Ignatius Ou, Shirish M. Gadgeel, Fabrice Barlesi, James Chih-Hsin Yang, Luigi De Petris, Dong-Wan Kim, Ramaswamy Govindan, Anne-Marie Dingemans, Lucio Crino, Herv é Léna, Sanjay Popat, Jin Seok Ahn, Eric Dansin, Emmanuel Mitry, Barbara Müller, Source Type: research